Celcuity's Gedatolisib Wins Approval, But Faces Uphill Battle for Market Access and Adoption

FDA Approves Celcuity's Revtorpyk for Breast Cancer

Celcuity has received FDA approval for its kinase inhibitor gedatolisib, marketed as Revtorpyk, for certain patients with locally advanced or metastatic breast cancer. The therapy is indicated for use in combination with AstraZeneca’s Faslodex, with or without Pfizer’s Ibrance, in HR-positive, HER2-negative patients without PI3KCA mutations, following progression on previous endocrine therapy. This approval, based on data from the Phase 3 VIKTORIA-1 trial, positions Celcuity uniquely in the market, as other PI3K/AKT drugs target PI3KCA-positive patients. The three-drug regimen demonstrated a median progression-free survival (PFS) of just over nine months, compared to two months for Faslodex alone. Celcuity anticipates a U.S. launch in late Q3.

• Revtorpyk's approval establishes a differentiated market position for Celcuity by specifically targeting HR-positive, HER2-negative metastatic or locally advanced breast cancer patients who lack PI3KCA mutations. This distinction is crucial, as existing PI3K/AKT inhibitors primarily focus on PI3KCA-positive patient populations, providing Revtorpyk a unique foothold and addressing a significant second-line patient segment.
• The FDA approval was supported by compelling data from the Phase 3 VIKTORIA-1 trial. The three-drug regimen (Revtorpyk plus Faslodex, with or without Ibrance) achieved a median progression-free survival (PFS) of just over nine months. In comparison, patients treated with Faslodex alone had a median PFS of two months, while Revtorpyk plus Faslodex (without Ibrance) resulted in a median PFS of 7.4 months, highlighting the significant clinical benefit.
• Celcuity plans to launch Revtorpyk in the U.S. in late Q3, supported by a comprehensive patient support program. The company also intends to submit a supplemental package for Revtorpyk based on data from a PI3KCA-mutant cohort, where the triplet regimen showed a 50% PFS benefit versus standard of care. Furthermore, Revtorpyk is being investigated in the Phase 3 VIKTORIA-2 trial as a potential first-line treatment option, indicating ongoing efforts to expand its therapeutic utility.

Addressing Unmet Needs in PIK3CA-Wildtype HR+/HER2- Metastatic Breast Cancer

Patients with PIK3CA-wildtype, HR-positive/HER2-negative metastatic breast cancer who progress after endocrine therapy face a therapeutic landscape marked by resistance, limited effective sequencing options, and a lack of validated biomarkers to guide decision-making. While CDK4/6 inhibitors combined with endocrine therapy have transformed first-line management, most patients eventually develop resistance—whether intrinsic or acquired—leaving few evidence-based options for subsequent lines of therapy, particularly in the absence of an actionable PIK3CA mutation.

• Absence of consensus second-line strategy: After progression on CDK4/6 inhibitors plus endocrine therapy, there is no established standard of care, and determining optimal subsequent treatment remains especially difficult for tumors lacking actionable mutations such as PIK3CA.

• Suboptimal efficacy of fulvestrant monotherapy: Real-world data indicate fulvestrant monotherapy is frequently used post-CDK4/6 inhibitor progression, but its clinical benefit is short-lived, with a reported median progression-free survival of only 3.18 months (range 1.9–5.3 months) in previously CDK4/6 inhibitor-exposed patients.

• Multiple, overlapping resistance mechanisms: Resistance to CDK4/6 inhibitors and endocrine therapy arises through diverse pathways, including p16 overexpression, heterozygous RB1 loss, and cyclin E overexpression driving resistance to both CDK4/6 and CDK2 inhibition—complicating the identification of a uniform therapeutic strategy.

• Reliance on chemotherapy with limited benefit: Once targeted and endocrine-based options are exhausted, treatment largely defaults to sequential chemotherapy, which offers only modest clinical benefit and carries cumulative toxicity burdens.

• Lack of predictive biomarkers: There remains an urgent unmet need for robust, validated biomarkers to guide treatment selection and sequencing, particularly for PIK3CA-wildtype tumors where mutation-directed therapies (e.g., PI3K inhibitors) are not applicable.

• Complex and evolving treatment landscape: The proliferation of targeted agents and combination regimens has increased the complexity of treatment sequencing, making optimal therapy selection challenging for clinicians in the absence of clear guidance for biomarker-negative populations.

• Toxicity management burden: Cumulative and treatment-related toxicities across multiple lines of therapy require careful clinical management, further complicating long-term treatment planning.

• Emerging but early-stage alternatives: Novel strategies—such as combined CDK4/6/CDK2 inhibition, TRAIL-based approaches targeting cancer stem cell-like activity, and PI3K inhibitor combinations independent of PIK3CA status—show preclinical promise but are not yet established as validated clinical options for this population.

Revtorpyk's Differentiated Role in the HR+/HER2- mBC Landscape

The addition of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to endocrine therapy (ET) has significantly improved outcomes for patients with HR-positive, HER2-negative advanced breast cancer compared to ET alone. A 2023 meta-analysis of nine randomized controlled trials involving 4,920 participants demonstrated that this combination substantially prolonged overall survival (OS; HR 0.76) and progression-free survival (PFS; HR 0.56). This benefit extended to PFS on next-line therapy (PFS2; HR 0.68) and delayed the time to first subsequent chemotherapy (HR 0.65). The combination also improved objective response rates and clinical benefit rates. The Phase III MONALEESA-2 trial provides a specific example, where ribociclib plus letrozole achieved a median OS of 63.9 months versus 51.4 months with placebo plus letrozole (HR 0.76) after a median follow-up of 6.6 years. This benefit was observed irrespective of PIK3CA mutation status.

While the CDK4/6 inhibitor class has established a new standard of care, emerging data suggests potential differentiation among agents and highlights the varying success of other targeted therapy combinations. A 2024 study, for instance, found no significant OS difference between palbociclib plus ET and ET alone, whereas ribociclib plus letrozole significantly improved PFS over letrozole alone. Propensity score weighting in this study suggested a potential survival advantage for ribociclib over palbociclib. Beyond CDK4/6 inhibition, the mTOR inhibitor everolimus combined with ET has also shown efficacy, with the BOLERO-2 and TAMRAD trials demonstrating significant PFS improvements. In contrast, combinations of ET with tyrosine kinase inhibitors (e.g., lapatinib, gefitinib) or trastuzumab have yielded more varied results and, in some cases, prohibitive toxicity, preventing their adoption as a standard therapeutic strategy for overcoming acquired endocrine resistance.

Expanding Gedatolisib's Potential: Future Indications and Lines

Gedatolisib's clinical development extends well beyond HR-positive, HER2-negative breast cancer, spanning multiple solid tumor types and combination strategies. Trials range from early-phase dose-finding studies to more targeted evaluations in molecularly defined populations, reflecting the drug's broad mechanistic rationale as a dual PI3K/mTOR inhibitor.

• Triple-negative breast cancer (TNBC) and ER-low breast cancer: A Phase I trial combined gedatolisib with cofetuzumab pelidotin (an antibody-drug conjugate against PTK7) across three dose cohorts (110 mg + 1.4 mg/kg; 180 mg + 1.4 mg/kg; 180 mg + 2.8 mg/kg) in patients with metastatic TNBC or ER-low (ER/PgR <5%, HER2-negative) disease following at least one prior chemotherapy line. Overall response rate was 16.7%, with an 18-week clinical benefit rate of 27.8% and median PFS of 2.0 months. Separately, gedatolisib plus talazoparib (PARP inhibitor) was evaluated in a Phase I/II trial (NCT03911973) using a 3+3 dose-escalation design in the safety run-in phase, reporting a 12% objective response rate, median PFS of 2.5 months, and median OS of 7 months.

• HER2-negative breast cancer with germline BRCA1/2 mutation: Also studied within the gedatolisib–talazoparib combination program, leveraging synthetic lethality in BRCA-mutant tumors.

• Advanced solid tumors (basket study): A four-arm, open-label Phase I study (NCT01347866) evaluated gedatolisib in combination with either the MEK inhibitor PD-0325901 or irinotecan. Arm C (gedatolisib + irinotecan) used a standard 3+3 dose-escalation design, while Arm D (gedatolisib + PD-0325901) employed a zone-based escalation design. The MTD for gedatolisib with irinotecan was estimated at 110 mg weekly; the MTD for the PD-0325901 combination was not reached at the highest dose tested (154 mg weekly).

• Colorectal cancer: Within the same basket study, gedatolisib plus irinotecan produced a ~5% response rate and clinical benefit in 16% of patients with advanced colorectal cancer, with a median PFS of 2.8 months.

• Ovarian and endometrial cancer: Preliminary activity was observed with gedatolisib plus PD-0325901 in KRAS-mutant ovarian cancer (three partial responses in five patients) and endometrial cancer (one partial response in one patient). Additionally, a Phase II study (B1271004) in recurrent endometrial cancer used a Simon two-stage design across four independent arms, stratifying patients into PI3K-basal or PI3K-activated cohorts based on stathmin expression. Xenograft studies further evaluated gedatolisib combined with palbociclib (CDK4/6 inhibitor) or fulvestrant (anti-estrogen), demonstrating tumor growth inhibition in both endometrial and ovarian cancer models.

• Cervical cancer: Included in preclinical cell-line and gynecologic cancer evaluations alongside endometrial and ovarian models, supporting rationale for combination with hormonal or CDK4/6-targeted therapy.

• Head and neck squamous cell carcinoma (HNSCC): Gedatolisib was combined with dacomitinib (pan-HER inhibitor) and radiation in low-passage xenograft models; however, the addition of gedatolisib did not enhance the antitumor effect of dacomitinib plus radiation despite confirmed inhibition of PI3K/mTOR pathway phosphorylation.

• Metastatic castration-resistant prostate cancer (mCRPC): Currently under investigation in a Phase 1/2 trial combining gedatolisib with darolutamide in patients previously treated with an androgen receptor (AR) inhibitor.

• Small-cell lung carcinoma (SCLC) and glioblastoma: Identified as mechanistically relevant settings, with the PI3K/AKT/mTOR pathway proposed as a feasible therapeutic target in SCLC, and a proposed combination with the EGFR inhibitor LASSBio-1971 in glioblastoma.

Across these programs, intervention models vary from basket-style, multi-arm open-label Phase I designs (parallel cohorts with distinct combination partners) to biomarker-stratified Phase II designs (e.g., Simon two-stage, stathmin-based stratification) and dose-escalation frameworks (3+3 and zone-based approaches), reflecting an evolving strategy to match gedatolisib's mechanism with tumor-specific vulnerabilities and combination partners.